A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma.
about
Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.Drug development for recurrent and refractory classical Hodgkin lymphoma.Targetable molecular pathways in classical Hodgkin's lymphoma.Therapeutic effects of thalidomide in hematologic disorders: a review.Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.Epstein-Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma.
P2860
A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
A phase II study of thalidomid ...... ients with Hodgkin's lymphoma.
@en
A phase II study of thalidomid ...... ients with Hodgkin's lymphoma.
@nl
type
label
A phase II study of thalidomid ...... ients with Hodgkin's lymphoma.
@en
A phase II study of thalidomid ...... ients with Hodgkin's lymphoma.
@nl
prefLabel
A phase II study of thalidomid ...... ients with Hodgkin's lymphoma.
@en
A phase II study of thalidomid ...... ients with Hodgkin's lymphoma.
@nl
P2093
P2860
P1433
P1476
A phase II study of thalidomid ...... tients with Hodgkin's lymphoma
@en
P2093
Jan McCrae
John Kuruvilla
Kevin Song
Michael Crump
Tony Panzarella
Tracy Nagy
P2860
P356
10.1080/10245330500276592
P577
2006-02-01T00:00:00Z